RAPID3 in Assessing Psoriatic Arthritis
My research shows that up to 50% of rheumatologists measure something in the course of their daily assessments, and RAPID3 is most popular, being employed by 31% of rheumatologists.
News
Top vasculitis takeaways from ACR 2021
There were several hot topics at ACR21. Here I concentrate on top abstracts in vasculitis.
GLORIA Study - Is Prednisone Harmful in Elder RA?
The GLORIA study (ABST# 1678) was a pragmatic, blinded placebo-controlled randomized trial from Dr. Martin Boers and colleagues where they assessed whether prednisolone (vs. placebo) use would alter clinical outcomes over 2 years.
An Old Friend – Methotrexate in Psoriatic Arthritis
Methotrexate (MTX) remains one of our most used and reliable tools against a variety of rheumatic diseases, including PsA. When the time comes, as it often does, to escalate from a MTX-monotherapy approach, we have several options. In clinic, initiation of these other medications has often been in the form of addition rather than substitution. But what do the patients want, and how much more is the MTX adding in those cases?
Perspectives on CV safety: JAK inhibitor (Tofacitinib) and TNF inhibitors
Safety comparisons of JAKi (tofacitinib) vs. TNFi from Oral Surveillance showed that, in patients with active RA on MTX and aged >50 years with one or more CV risk factors, that there was numerically more MACE events, malignancies, and VTE especially in higher dose.
More severe COVID-19 outcomes in African American, Hispanic individuals with SLE
A study from ACR21 convergence discussing data from the Global Rheumatology Alliance (GRA) describes the association between race/ethnicity on COVID-19 outcomes specifically in lupus patients.
RheumNow Podcast - ACR 2021 Rehash (the good stuff..)
The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.
Racial/ethnic disparity in U.S. lupus nephritis mortality
At #ACR21, the plenary session included an analysis of deaths from SLE throughout the US comparing 1999 to 2019 (Abstract #0454).
Emapalumab for the treatment of macrophage activation syndrome
Macrophage activation syndrome (MAS) is a term commonly used by rheumatologists to describe a potentially life-threatening complication of systemic inflammatory disorders, most commonly occurring in people with systemic juvenile idiopathic arthritis (sJIA) and systemic lupus erythematosus (SLE).
Predicting RA, and Treatment of Subclinical Arthritis
Identifying patients that will develop RA in situations of seropositivity without overt clinical arthritis or identifying patients with undifferentiated oligo/polyarthritis that will develop RA remains a challenge in the field of rheumatology.
Psoriatic Arthritis: "What Matters" to Patients, Physicians
A study presented today by Mease et al. addresses the vital gap between what patients and physicians consider disabling because of PsA, and emphasizes “what matters” in a daily clinical encounter while dealing with PsA.
Can "Ultra-low" dose Rituximab work for RA?
The REDO trial presented data in abstract 1443 in an oral presentation challenging how low we can go with rituximab for rheumatoid arthritis. Their study randomized 118 patients with rheumatoid arthritis to 1000 mg, 500 mg, and "ultra-low" dose 200 mg.
RA: Cardiovascular Risk Stratification and Potential Predictors of Risk
Early cardiovascular disease assessment and management is critical at diagnosis in patients with Rheumatoid Arthritis (RA).
Day 4 Report from ACR21
My favorite three presentations from day 4 (Tuesday) at ACR 2021 included the following.
